Support of discovery programs is essential to providing integrated drug development services. The key is to have the expertise to be able to tackle complex matrices along with any biomarker component.
In this presentation, featured speakers will highlight bioanalytical challenges in drug discovery and some potential solutions. Examples presented will include:
- The approach taken in drug discovery with the selection of an appropriate system calibration matrix
- How to tackle highly unstable compounds
- Working around micro sample requirements (i.e., ocular tissues, human tears, rat milk)
- Processing complex matrices (ear wax, sputum, lung)
Gene Ray, Ph.D., Senior Scientific Advisor, KCAS
Dr. Gene Ray is the Senior Scientific Advisor at KCAS for small molecules and Director of Business Development. Since joining the company in 1990, he has gained expertise in a full range of bioanalytical techniques including LC-MS/MS, GC-MS/MS, ELISA, RIA, protein binding and mass balance investigations. He also serves as technical consultant and board member of a Phase I Investigation Review Board. Gene has experience developing novel methods and has acted as the Principal Bioanalytical Investigator for a vast number of client programs analyzing hundreds of pharmaceutical compounds in blood, urine, and various tissues. Gene has recently presented numerous scientific findings at AAGL, AAPS, ACOG, ACT, ASCPT, ASMS, ASRM, FDA/CDER, SOT, TSRC and WCE. He also is an NIH grant recipient. He previously served as the Assistant Director for numerous analytical chemistry programs for the National Cancer Institute while at Midwest Research Institute.Message Presenter
Lawrence Goodwin, Executive Director Bioanalytical Services, KCAS
Mr. Goodwin is the Executive Director of Bioanalytical R&D and LC-MS/MS Services at KCAS Bioanalytical & Biomarker Services in Shawnee, Kansas. Business development, strategic planning, portfolio expansion, client-based solutions, and driving key scientific objectives for bioanalytical R&D and LC-MS/MS Services are among his primary responsibilities. Mr. Goodwin brings with him the breadth of knowledge to provide scientific and technical leadership across the drug development spectrum including Discovery, Safety Assessment, and Biologics Testing Solutions areas; he has been with KCAS since January 2018.
Lawrence Goodwin has significant drug development aptitude within pharmaceutical and CRO industries. He has lead teams responsible for bioanalytical programs from Discovery through New Drug Application filings. He has more than 25 years’ experience in the Life Sciences industry which includes most recently Eli Lilly and Company and Charles River Laboratories. Leveraging tandem mass spectrometry, Lawrence has made significant contributions in the fields of Bioanalytical, Analytical, Safety Assessment, Biotherapeutics, and Integrated Drug Discovery. He has authored or co-authored more than 35 papers and presentations and provided over 150 internal documents.
Lawrence received his BS in Biological Chemistry from Fontbonne University, St. Louis, Missouri in 1986 and graduated Cum Laude. His continuing education includes the following areas: executive leadership, people and resource management, advanced instrumentation, and GLP training. He has been the recipient of numerous awards both as an individual contributor and as a leader, especially in the areas of tandem mass spectrometry, data management, and process/work-flow efficiency. He is the former chair of the Eli Lilly Mass Spectrometry group and is an active member of American Society for Mass Spectrometry, and a current member of the executive leadership team at KCAS.Message Presenter
Who Should Attend?
Senior management, analysts and scientists working in the discovery phase within the bioanalytical and analytical space
What You Will Learn
Join this webinar to learn how to:
- Select an appropriate system calibration matrix
- Tackle highly unstable compounds
- Work around micro sample requirements (i.e., ocular tissues, human tears, rat milk)
- Process complex matrices (ear wax, sputum, lung)
KCAS Bioanalytical & Biomarker Services
KCAS Bioanalytical & Biomarker Services is a contract laboratory with 39+ years of bioanalytical expertise. Centrally located in Kansas City, KCAS provides small- and large-molecule PK, immunogenicity, and biomarker analysis operating a variety of equipment platforms to service a wide range of therapeutic areas. KCAS’ team leverages a highly scientific staff with an average tenure in the field of bioanalysis/biomarker analysis of 22 years to provide clients of all sizes with expertise in robust assay development, validation, and sample analysis under fit-for-purpose Non-GLP, GLP, and GCP conditions for discovery, preclinical and clinical studies. Our teams have developed and validated more than 5,500 bioanalytical assays and have undergone 16 FDA inspections.